3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

It’s one of the most explosive sectors in the market — but also one of the riskiest. Biotech investors, beware. Small-cap biotech stocks can be extremely volatile… but if you know what to look for, the payoff can be massive. In this video, MarketBeat contributor Chris Markoch breaks down 3 small-cap biotech stocks with major FDA catalysts in motion — including clinical trial breakthroughs, fast track designations, and upcoming approvals that could trigger major moves. One stock could see gains of over 117% from where it’s trading today. Another is working in the red-hot gene editing space — a segment set for explosive growth. If you’re looking for biotech opportunities with high risk and high reward potential, this is the list to watch. Click here for the exclusive article 5 High-Risk, High-Reward Stocks With Serious Momentum: https://marketbeat.link/momentum Explore MarketBeat’s FDA tools here: https://www.marketbeat.com/fda-events/ Subscribe now to stay ahead of the market: https://marketbeat.link/youtube Text ’YouTube’ to 68285 for FREE SMS breaking news alerts on top stocks. Get MarketBeat All Access FREE for 30 Days: https://marketbeat.link/access #BiotechStocks #SmallCapBiotech #FDAApproval #GeneEditing #ClinicalTrials #Investing #StockMarket #GrowthStocks #HighRiskHighReward #StocksToWatch #MarketBeat #StockAnalysis #ExplosiveStocks #StockNews #BiotechInvesting #marketbeat DISCLAIMER: MarketBeat’s videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.